Longevity screening is the testing of a well person for disease and risk before any symptom appears. In the guides we publish here, this is where the gap is widest between what a program sells and what a guideline body has graded.
The U.S. Preventive Services Task Force (USPSTF) gives a Grade A or B to a defined list of screening services for non-pregnant adults. The eleven listed below are the ones that overlap most with a paid longevity panel. The full list also covers screening for depression, anxiety, unhealthy alcohol and drug use, and several infections. Almost everything a longevity panel adds beyond that graded list carries no grade from anyone.
The Verdict
Longevity Screening Is Two Products under One Name
Longevity screening is two separate products sold under one name. The first is the preventive testing a primary care physician already owes you, set by age and sex and graded for whether it improves outcomes. The second is a private panel bolted on top: more blood markers, body composition, fitness testing, and in the more expensive programs, imaging.
Those two halves get quoted as one price and read as one recommendation. They are not equally supported. A grade exists for the first half because someone ran the trials and weighed the harms of screening against the benefit. For most of the second half, no body has graded it either way, which is a different situation from a body having looked and said no.
The Screening Tests with a Grade Behind Them
USPSTF Grade A and B recommendations are the screening services with evidence that screening improves outcomes for the population named in the row. The grade also decides who pays. Under the Affordable Care Act, A and B rated services are covered by most non-grandfathered US plans with no copay. The population column sets your eligibility. What you are willing to spend does not change it.
| Screening | Who it applies to | USPSTF grade | Interval or note |
|---|---|---|---|
| High blood pressure | Adults 18 and older with no known hypertension | A | Readings outside the clinic before any diagnosis |
| Colorectal cancer | Adults 45 to 49 (Grade B) and adults 50 to 75 (Grade A) | A and B | Colonoscopy every 10 years, or an annual stool test |
| Cervical cancer | Women 21 to 65 | A | Every 3 years by cytology, or every 5 years with human papillomavirus (HPV) testing from 30 |
| Breast cancer | Women 40 to 74 | B | Every 2 years |
| Lung cancer | Adults 50 to 80 with a 20 pack-year history who smoke now or quit within 15 years | B | Annual low-dose computed tomography (CT) |
| Prediabetes and type 2 diabetes | Adults 35 to 70 who have overweight or obesity | B | Every 3 years may be reasonable after a normal result |
| Cholesterol, for a statin decision | Adults 40 to 75 with a risk factor and 10-year risk of 10% or more | B | No interval stated |
| Hepatitis C | Adults 18 to 79 | B | Once for most adults |
| Human immunodeficiency virus (HIV) | Adolescents and adults 15 to 65 | A | No interval stated |
| Osteoporosis | Women 65 and older, and postmenopausal women under 65 with a risk factor | B | No interval stated |
| Abdominal aortic aneurysm | Men 65 to 75 who have ever smoked | B | One ultrasound, once |
Two rows sit differently from the rest. Colorectal screening starts at 45, where the American Cancer Society and USPSTF now agree. The society adds that screening should continue to 75 in anyone whose life expectancy is over 10 years. Prostate screening appears nowhere above because it is graded C for men 55 to 69, which makes the prostate-specific antigen (PSA) decision an individual one. It is graded D for men 70 and older.
Where the Longevity Industry and the Guidelines Disagree
Most of what distinguishes a paid longevity panel from ordinary preventive care is ungraded rather than disproven. The table below sets what programs typically offer against the current official position on the same test. We wrote the third column from the guideline documents themselves rather than from any program's summary of them. Two of those positions come from outside USPSTF. The American College of Radiology (ACR) sets the position on screening imaging, and the Food and Drug Administration (FDA) has not cleared or approved Galleri, the multi-cancer blood test.
| Test | What longevity programs offer | The current official position |
|---|---|---|
| Coronary artery calcium score | Offered as a standard add-on | USPSTF graded it I in 2018. The ACC and AHA raised it to their strongest class in March 2026 for refining a treatment decision |
| Lipoprotein(a) | Offered inconsistently across panels | The 2026 ACC and AHA guideline asks for it at least once in every adult lifetime |
| High-sensitivity C-reactive protein | Standard on almost every longevity panel | USPSTF graded it I as an addition to cardiovascular risk assessment |
| Whole-body MRI | Marketed as early cancer detection | The ACR does not find the evidence sufficient in people with no symptoms, risk factors or family history |
| Multi-cancer blood test | Sold as a cancer screen | Galleri is not cleared or approved by the FDA, and is meant to be used in addition to recommended screening |
| Vitamin D level | Routine on longevity panels | USPSTF graded screening in asymptomatic adults I in 2021 |
| Thyroid function | Routine on longevity panels | USPSTF graded screening in non-pregnant asymptomatic adults I in 2015 |
| Epigenetic age clock | Sold as the headline result | No guideline body grades it for screening |
USPSTF and the two cardiology bodies now take opposite positions on the CAC score. USPSTF concluded in July 2018 that evidence was insufficient to assess adding a CAC score, high-sensitivity C-reactive protein (hsCRP), or an ankle-brachial index to standard risk assessment. The ACC and AHA moved the other way in March 2026, raising CAC to their strongest recommendation class for refining risk beyond a PREVENT score. PREVENT is the AHA calculator that estimates 10-year and 30-year risk. Both readings are defensible and they answer different questions. USPSTF asks whether population-wide use of the test prevents events. The cardiology guideline asks whether the result helps a physician and a patient settle a statin decision that is genuinely balanced.
That same guideline made lipoprotein(a) a once-in-a-lifetime measurement for every adult. It is the first time either body has asked for universal testing of that marker. If a program is running a large panel on you and lipoprotein(a) is not on it, that is worth asking about before you pay. The ungraded items are not automatically worthless either. Whole-body MRI is covered separately on our full-body MRI scan page, which starts from the ACR statement on screening total-body MRI.
What Guidelines Recommend Against
A Grade D means USPSTF looked at the test and concluded it has no net benefit, or that its harms outweigh its benefits, in people without symptoms. That is a stronger statement than the ungraded items above. Several Grade D tests are ones people ask for by name at a longevity clinic:
- PSA-based prostate cancer screening in men 70 and older
- Screening for carotid artery stenosis in adults with no symptoms
- Resting or exercise electrocardiography for cardiovascular risk in adults at low risk
- Screening for ovarian, pancreatic, thyroid or testicular cancer in the general adult population
The harm in each case is the same shape. A test with a low chance of finding real disease produces false positives. Those false positives lead to biopsies, surgery and follow-up imaging in people who were never going to be harmed by the disease being looked for. If a program offers you one of these four, ask what it knows that USPSTF does not, and get the answer before the scan.
Who Should Skip Longevity Screening
A healthy adult under 40 with no family history gets very little from a paid longevity panel. Almost none of the graded screening has started yet at that age, and a normal ungraded marker carries no action with it. Blood pressure and a lipid panel are the sensible pair in that decade, and both are ordinary primary care. Anyone who would not act on a finding should also skip it. A borderline result you do not treat still generates the retest, the second opinion, and the worry.
We would change this answer on one condition. A program would have to publish outcome data showing that its members detect treatable disease earlier than matched adults on guideline screening alone. That result would settle the ungraded half of the panel. No program has published the comparison, and none is running the trial. Until one does, the graded list is the part with evidence behind it.
Frequently Asked Questions
What is longevity screening?
Longevity screening is testing a person with no symptoms for disease and risk, on the theory that finding something early changes how long and how well they live. In practice it bundles two different things. The first is the set of screening tests that national guideline bodies have graded. Those are the ones a primary care physician already owes you, such as blood pressure, colorectal cancer, and a cholesterol panel for the statin decision. The second is everything a private program adds on top: a much larger biomarker panel, sometimes imaging, and sometimes an epigenetic age estimate. Only the first set has been graded for whether screening improves outcomes.
What tests are included in longevity screening?
A typical private program runs a 40 to 120 marker blood panel and body composition by dual-energy X-ray absorptiometry (DEXA). Most add a fitness measure such as maximal oxygen uptake (VO2 max), and the more expensive ones add a coronary artery calcium scan or a whole-body MRI. Guideline-graded screening is set by your age, sex and risk factors rather than by your budget. The eleven items in the table above are the USPSTF Grade A and B screening recommendations that overlap most with what a longevity panel sells. The full A and B list is longer and also covers screening for depression, anxiety, unhealthy alcohol and drug use, and several infections. How many apply to you at any one age depends on your age, sex, smoking history and risk factors.
Is longevity screening worth it?
The graded half is worth it and mostly costs very little, because blood pressure, colorectal, cervical and lung cancer screening are covered preventive services under most US plans. The ungraded half turns on one question. Would a result change what you do? A coronary artery calcium score of zero that lets you defer a statin is a decision that changed. A 90 marker panel that returns a handful of borderline flags you then retest is usually a purchase of retests and worry. Our page on longevity clinic cost covers what the total year-one figure comes to.
Does insurance cover longevity screening?
The USPSTF Grade A and B services are covered without cost sharing under most non-grandfathered US plans. That coverage follows directly from the grade. Anything graded C, D or I is generally not covered as preventive care, and most of a longevity panel carries one of those grades. Whole-body MRI, epigenetic clocks and large biomarker panels are almost always paid for directly. Ask the program to itemize before you pay, because the graded tests inside a paid package are often billable to insurance separately.
What screening tests do guidelines recommend against?
The USPSTF currently gives a Grade D, meaning it recommends against the service, to several tests that people ask for by name. Those include PSA-based prostate cancer screening in men 70 and older, and screening for carotid artery stenosis in adults with no symptoms. They also include resting or exercise electrocardiography for cardiovascular risk in adults at low risk, and screening for ovarian, pancreatic, thyroid and testicular cancer in the general adult population. A Grade D is not a statement that the disease does not matter. It means the screening test causes more harm than benefit in people without symptoms.
How often should you get screened?
Interval is set per test rather than per person, and only some of the graded recommendations state one. Colorectal screening runs every 10 years by colonoscopy, or annually by stool test. Cervical screening runs every 3 years by cytology, or every 5 years with HPV testing from 30. Breast screening runs every 2 years from 40, and lung cancer screening annually while you remain eligible. The abdominal aortic aneurysm ultrasound is a single scan, once, for men 65 to 75 who have ever smoked. Annual repetition of a large biomarker panel has no graded interval behind it at all.
Can longevity screening detect cancer early?
Four cancers have graded screening behind them for average-risk adults: colorectal, cervical, breast, and lung in people with a heavy smoking history. Those four are where early detection has been shown to change mortality. Blood tests that claim to detect many cancers at once are a different proposition. Grail states plainly that Galleri "has not been cleared or approved by the Food and Drug Administration." Galleri's own site adds that the test "should be used in addition to routine cancer screening tests recommended by a healthcare provider." Our Galleri review covers what its published detection rates look like by stage.
What is the difference between longevity screening and an annual physical?
An annual physical is a visit. Longevity screening is a menu of tests that may or may not be ordered at that visit. The overlap is larger than most programs imply. Blood pressure, the lipid panel, glycated hemoglobin (HbA1c) where you qualify, and the age-appropriate cancer screenings all belong to ordinary primary care and are already covered. What a private program adds is volume of markers, imaging, and interpretation against optimal rather than reference ranges. Our page on normal versus optimal ranges covers why that reframing changes so many results from green to yellow. The practical next step on longevity screening is to ask your physician which graded screening services you are eligible for today. Decide separately about anything a program wants to add on top.
Related
- What is a longevity clinic — the four clinic models and how to vet one
- Longevity clinic cost — the full price breakdown and the insurance position
- Full-body MRI scan — what a screening MRI finds and what it costs you afterwards
- Cancer screening blood test accuracy — the published detection rates for the multi-cancer tests
- Biomarker guide — what to test and what each result means
- Normal vs optimal ranges — the reference-range question these panels turn on